Reading time 7 minutes

Aktualisiert – June 8, 2026

R-CHOP is used as chemotherapy for cancer.

The following post provides a comprehensive overview of the R-CHOP chemotherapy regimen, which is one of the most important standard therapies for aggressive B-cell lymphomas, such as diffuse large B-cell lymphoma (DLBCL).
In addition to explaining the individual active ingredients Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone, their mechanisms of action, pharmacology, typical side effects, and relevant risks and monitoring strategies are presented in detail.

Particular emphasis is placed on the temporal progression of therapy over multiple cycles. The schematic cycle diagrams illustrate typical hematological changes such as neutropenia, thrombocytopenia, and anemia, explain cumulative toxicities—particularly neurotoxicity and cardiotoxicity—and classify these based on published study data.
In addition, supportive measures such as G-CSF prophylaxis, adjunctive anti-infective therapies, and evidence-based supplementation are described, and potentially problematic natural substances and drug interactions are listed.

The content is intended to provide a scientifically grounded overview and illustration of typical R-CHOP treatment courses; however, it is not a substitute for an individual medical evaluation or treatment decision.

Anyone affected and – additionally – seeking professional advice can at any time receive individual Consulting and/or research requests.

R-CHOP

R-CHOP is a CHOP chemotherapy regimen, expanded with the active ingredient Rituximab. The individual active ingredients have different half-lives and also different metabolisms.

Metabolism refers to the transformation or breakdown of chemical structures of active substances. In this process, prodrugs are first converted into their actually effective form in the liver.
The goal of metabolism is to make active substances more water-soluble (hydrophilic) so that they can be excreted and thus eliminated via the kidneys (renal, urine) or via the liver and bile (biliary or fecal, via stool).
With impaired kidney or liver function (insufficiency), metabolism takes longer, which must be taken into account when deviating from the normative data.

Active ingredients

Rituximab

Monoclonal antibody · CD20 antagonist · IgG1κ-chimera

Substance class
Chimeric monoclonal antibody (murine/human IgG1κ). Molecular weight: ~145 kDa. First commercially approved antibody therapeutic for lymphomas.

Target structure
CD20 Antigen: 33–37 kDa phosphoprotein on the surface of pre-B and mature B lymphocytes. Not expressed on hematopoietic stem cells, plasma cells, or other tissue cells → B-cell reconstitution possible after therapy; antibody levels (plasma cells) largely preserved initially.

Mechanism of action (4 effector mechanisms)

ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity): Fc-mediated activation of NK cells, macrophages, neutrophils.
CDC (Complement-Dependent Cytotoxicity): Activation of the classical complement pathway via C1q binding → membrane attack complex → cell lysis. Dependent on CD20 expression density (sigmoidal correlation).
Direct apoptosis induction: Cross-linking of CD20 → inhibition of IL-10, inhibition of IL6/STAT3 signaling pathway, activation of c-Myc, disruption of anti-apoptotic protection.
ADCP (Antibody-dependent phagocytosis): Fc receptor-mediated uptake by macrophages.

Pharmacokinetics
– Metabolism: Hepatic via the RES (reticuloendothelial system) and immune cells
– Half-life (t½): ~22 days after first administration, increases with repeated administrations to ~29 days (reduced CD20+ target cells = slowed clearance)
– B-cell depletion: Complete within the first 3 weeks.
- B-cell recovery begins after ~6 months
– Median normalization: ~12 months after the end of treatment. CD19+ B cells were depleted in 83% of patients for up to 6–9 months after rituximab.

Dosage for R-CHOP
Cycle 1: 375 mg/m² IV (intravenous) as an infusion, Day 1.
Starting with cycle 2, alternatively: 1,400 mg s.c. (subcutaneously) as a fixed-dose formulation (+ hyaluronidase enhancer).

Approved Indications
Non-Hodgkin lymphomas (especially DLBCL, follicular lymphoma), CLL (chronic lymphocytic leukemia), Rheumatoid arthritis (2nd line), ANCA-associated vasculitides (GPA, MPA), Pemphigus vulgaris.

Adverse effects (selection)
Infusion reactions (common with the first dose: fever, chills, hypotension)
Premedication mandatory. Immunosuppression
→ increased risk of infection (reactivation of HSV, VZV, HBV!)
→ HBsAg/Anti-HBc screening is mandatory before therapy). PML (progressive multifocal leukoencephalopathy) caused by JC virus, rare but life-threatening. Late-onset neutropenia (LON) possible up to months after the end of therapy.

Reference sources

C – Cyclophosphamide

Alkylating agent · Prodrug · Oxazaphosphorine · Nitrogen mustard derivative

Substance class
Bifunctional synthetic alkylating agent, oxazaphosphorine derivative. ATC code: L01AA01. Inactive prodrug, requires activation in the liver.

Mechanism of action
Following hepatic activation (see Metabolism), phosphoramide mustard causes covalent alkylation of DNA at the N7 position of guanine.
Consequences: Single and double-strand breaks in DNA, inhibition of DNA replication, inhibition of transcription (DNA→RNA), blockade of cell division → apoptosis of tumor cells.
Cell cycle non-specific, affecting all cell phases.

Metabolism (hepatic - CYP450)
– Hydroxylation by CYP2B6 (major enzyme), CYP2A6, CYP2C9, CYP2C19, CYP3A4 → 4-hydroxycyclophosphamide.
– Equilibrium with tautomer aldophosphamide.
– Activation
Spontaneous decomposition → phosphoramide mustard (active alkylating agent) + acrolein (nephrotoxic).
– Inactivation
Oxidation by ALDH (Aldehyde Dehydrogenase) → inactive metabolites (e.g., Carboxycyclophosphamide).
Cave: Cyclophosphamide induces its own metabolism → repeated administration results in increased clearance and a shorter half-life.

Pharmacokinetics
– Oral bioavailability: >75% %.
– Half-life (t½): 3–12 hours (adults: typically 4–9 hours).
– Elimination: Primarily as metabolites via the kidneys; 10–20% of % administered intravenously is excreted unchanged via the kidneys; 4% of % is excreted via the bile.
– Total body clearance: 63 ± 7.6 L/kg.

Dosage form and dosage for R-CHOP
i.v. as a short infusion (from powder, dissolved in infusion solution) or orally (tablet/capsule).
Standard CHOP dose: 750 mg/m² IV on day 1 of the cycle.

Urotoxicity & Mesna Protection
Acrolein (toxic byproduct) accumulates in the urinary bladder → hemorrhagic cystitis.
Mandatory prophylaxis: Mesna (sodium salt of 2-mercaptoethanesulfonic acid) at 20% of the cyclophosphamide dose, administered intravenously at 0 h, +4 h, and +8 h. Mesna binds acrolein in the urine → non-toxic thioether.

Important Interactions & Precautions
Reduced kidney or liver function → Dose adjustment required (impaired activation and elimination).
– St. John's Wort: CYP3A4 inducer → increased clearance → reduced efficacy (see Contraindications Supplementation).
– Embryo/fetotoxic, impairs reproductive ability → mandatory contraception. Discuss cryopreservation of germ cells before starting therapy.

Adverse effects (selection)
– Myelosuppression (Nadir days 9–12, recovery ~days 15–21)
– Reversible Alopecia
Nausea/vomiting
– Hemorrhagic cystitis (without Mesna protection)
Hyponatremia (SIADH-like with high-dose therapy)
– Secondary malignancies (leukemias and bladder carcinoma in long-term therapy).

Reference sources

H – Hydroxydaunorubicin (Doxorubicin)

Anthracycline antibiotic · Topoisomerase II inhibitor · intercalator

Substance class
Anthracycline, naturally occurring antibiotic from Streptomyces peucetius var. caesius. Cell-cycle nonspecific. Trade names: Adriblastin®, Adriamycin®. Liposomal forms: Caelyx® (PEG-liposomal), Myocet® (non-PEG-liposomal).

Mechanism of action (3 main mechanisms)
DNA intercalation
Intercalation between adjacent DNA base pairs → steric hindrance, inhibition of RNA and DNA synthesis
– Topoisomerase II Inhibition (»Poison« Mechanism)
Blockade of the type II enzyme in the state of DNA strand breaks → persistent single- and double-strand breaks → apoptosis
Reactive oxygen species (ROS)
Enzymatic single-electron reduction → Hydroxyl radicals (OH•) → oxidative DNA and membrane damage → cytotoxicity (tumor effect) and cardiotoxicity (undesired side effect).

Cardiotoxicity — cumulative dose-dependent
Mechanism
Inhibition of topoisomerase IIβ in cardiomyocytes + ROS generation + mitochondrial dysfunction + iron metabolism disorder → irreversible cardiomyopathy.
Thresholds for increased clinical observation
≥250–300 mg/m² (increased vigilance), ≥500 mg/m² (risk ~16 %), ≥700 mg/m² (risk ~48 %)
Manifestation
Mostly as dilated cardiomyopathy with reduced LVEF, signs of heart failure (dyspnea, edema, pleural effusion), often months to years after therapy completion
– Monitoring Obligated
ECG, LVEF-Echocardiography, Biomarkers BNP/NT-proBNP and Troponin.
– In case of reduced pump function
ACE inhibitors + beta-blockers → prognostically favorable.

Pharmacokinetics
Intravenous application only (minimal oral bioavailability).
Distribution
Rapidly into tissue; no relevant blood-brain barrier passage
Metabolism
Hepatic → Doxorubicinol (active main metabolite) + Aglycone derivatives
– Elimination
Predominantly biliary/fecal
Half-life
Triphasic - initially very short (distribution phase), intermediate ~3 h, terminal ~20–48 h.
- Cave Bilirubin
Elevated bilirubin levels or cholestasis → significantly prolonged plasma half-life → increased toxicity. Dose reduction in cases of impaired liver function or after gallbladder resection.

Dosage form and dosage for R-CHOP
For intravenous infusion only.
– Standard dose CHOP
50 mg/m² Day 1
– Liposomal formulations (Caelyx®, Myocet®)
Reduced cardiotoxicity, with cumulative doses >450 mg/m² no cardiac events under pegylated liposomal form (vs. conventional).

Important Interactions & Precautions
– Trastuzumab (Herceptin®)
Pronounced additive cardiotoxicity + extremely long trastuzumab half-life (~28 days) → anthracyclines only ≥24 weeks after the end of trastuzumab therapy
– Embryo/fetotoxic, affects reproductive capacity → mandatory contraception
– Liver function tests (transaminases, bilirubin)
Temporary increase expected during therapy; adjust dose if increase persists.

Reference Sources (Clickable)

O – Oncovin (Vincristine)

Vinca alkaloid · Mitosis inhibitor · Tubulin inhibitor

Substance class
Vindoline alkaloid, semi-synthetic from Catharanthus roseus (Madagascar periwinkle). ATC: L01CA02. First isolated in 1961, in clinical use since the early 1960s. Only available as an injection solution, IV ONLY (intrathecal = almost always fatal!).

Mechanism of action
Binding to β-tubulin → Inhibition of α- and β-tubulin polymerization into microtubules → Blockade of mitotic spindle apparatus formation → Cell cycle arrest in metaphase (M-phase).
– Side effect
Axonal transport of microtubules in neurons is also impaired → peripheral neuropathy (dose-limiting toxicity).
Additionally, p53 pathway → apoptosis induction; PI3K/AKT/mTOR inhibition → reduced cell proliferation.

Pharmacokinetics – Triphasic
Initial HWZ: ~5 minutes (distribution phase, rapid tissue uptake).
Intermediate HWZ: ~2.3 hours
Terminal hardware: ~85 hours (highly variable between individuals).
Distribution
Prefers liver, spleen, kidney, lung
Low CNS penetration (P-glycoprotein substrate)
Metabolism: Hepatic via CYP3A4
– Elimination
~70 % biliary/fecal, only 10–20 % renal
– Liver insufficiency → prolonged half-life + increased side effects.
– Dose reduction if direct serum bilirubin is >3 mg/dL: initial dose –50 %.

Dosage form and dosage for R-CHOP
For intravenous short-term infusion only (NOT intrathecal; mortality rate nearly 100%!)
– Standard adult dose
1.4 mg/m² i.v., maximum single upper limit 2 mg (total dose cap).
Extravasation risk
Tissue damage from paravenous administration → strict vein control or central venous catheter.

Neurotoxicity — dose-limiting side effect
Peripheral Neuropathy
Almost all patients initially present with sensory disturbances (tingling, numbness distally); motor deficits may occur with continued progression.
Jaw pain, spermatic cord nerve pain, autonomic neuropathy (constipation to ileus, urinary retention, hypotension).
– With severe neurotoxicity/paresis
Interrupt treatment, then resume with a 50 % dose.

Important Interactions
– CYP3A4 inhibitors (azole antifungals such as fluconazole, voriconazole)
elevated vincristine levels → increased neurotoxicity. Only if no alternative is available!
– G-CSF/GM-CSF
Reported with frequent atypical neuropathies with distal burning/stinging when given concurrently.
St. John's wort
CYP3A4 inducer → decreased vincristine levels → loss of efficacy.

Reference sources

Prednisone

Synthetic glucocorticoid · Prodrug of prednisolone · Immunosuppressant

Substance class
Synthetic glucocorticoid, prodrug. Converts in the liver to the active metabolite prednisolone via reduction at the C-11 keto group. ATC: H02AB07. In severe liver insufficiency, use prednisolone directly (no activation capacity).

Mechanism of action
Binding to intracellular glucocorticoid receptors in the cytoplasm → Translocation into the cell nucleus → Binding to GRE (Glucocorticoid Response Elements) in DNA → Transcriptional regulation (genomic mechanism, onset of action delayed by 30–60 min).
Anti-inflammatory
Inhibition of inflammatory cell immigration, inhibition of the release of immunomodulatory mediators (cytokines, chemokines)
Immunosuppressive
Suppression of T and B lymphocyte activity
Antiproliferative
Relevant in the context of lymphoma therapy. Relative potency: 4× stronger than endogenous cortisol (hydrocortisone) with predominantly glucocorticoid, less mineralocorticoid effect.

Pharmacokinetics
Oral resorption
Rapid and complete. Peak plasma level: 1-2 h after ingestion.
– Plasma half-life (t½)
2–4 hours
Biological half-life
12-36 hours (significantly outlasts plasma half-life, genomic mechanism)
Protein binding
Reversible binding to glucocorticoid-binding globulin + albumin.
– Elimination
~98 % renal as free and conjugated metabolites
Liver failure
Reduced clearance, prolonged half-life, increased free active fraction in hypoalbuminemia.

Dosage for R-CHOP
100 mg/d orally (or IV) on days 1–5 of the cycle.
– Standard schema CHOP
5-day short-term exposure, no tapering phase needed for short-term therapy ≤5 days.

Cushing's Disease Dosage & Side Effect Profile
– Cushing's syndrome dose
7.5 mg/day for long-term administration
Metabolic
Hyperglycemia (Diabetes mellitus), hypercholesterolemia, hypertriglyceridemia, sodium retention with edema, potassium loss (caution: cardiac arrhythmias), weight gain
Endocrine
Adrenal suppression with continuous therapy. Cushing's syndrome (moon face, central obesity, buffalo hump) with supraphysiological continuous doses
– Hello
Steroid-induced osteoporosis (cumulative, cycle-dependent relevance → Ca²⁺ + Vit D supplementation mandatory)
Gastrointestinal
Increased ulcer/gastritis risk (decreased mucus production, increased stomach acid) → PPI prophylaxis days 1-5
Infectious disease
Increased risk of infection, reactivation of latent infections (HSV, VZV, HBV, Strongyloides!)
Psychiatric
Irritability, euphoria, sleep disturbances, depression, mania, hallucinations.

Indications in underlying diseases with increased Cushing's sensitivity
With the following pre-existing conditions, the risk of Cushing's and the side effect threshold are lowered; special vigilance is required:
Rheumatoid arthritis, polymyalgia rheumatica (PMR), relapsing polychondritis, multiple sclerosis (MS), glomerulonephritides, Crohn's disease, ulcerative colitis.

Reference sources

R-CHOP - Cycles

The following tabular overviews represent the average course observed in clinical studies.

Instructions for Handling Tables

Mouse-over over the timeline symbolizing the duration of action of an active ingredient causes a pop-up to be displayed with information about the active ingredient, dosage, level, supplementation, side effects, or contraindications.

Mouse-over on hematologic trend curves displays nadir data, trends, effects, prophylaxis, monitoring, and intervention notes.

Active ingredients, hematologic toxicity, and iron metabolism

1. Cycle

Schematic timeline (21 days, days 1–21 of the entire treatment).

Evidence base for the anchor points:
[1] Coiffier et al., GELA, N Engl J Med. 2002;346(4):235–242 PubMed: PMID 11807147): ANC-Nadir Median 0,4 G/L; Grad 3–4 Anämie 14%; Grad 3–4 Thrombozytopenie 6%
[2] Aapro et al., EORTC G-CSF, Eur J Cancer 2011;47:8–32
[3] GELA 2002 [1] (per-Zyklus-ANC-Daten: stabile Nadir-Tiefen über Zyklen 1–8; Pre-Zyklus-ANC sinkt graduell)
[4] Clausen MR & Ulrichsen SP et al., Leuk Lymphoma 2019;60(8): Grad-4-Neutropenie in 45% (432/965 Patienten) nach Zyklus 1 R-CHOP.
Iron parameters (ferritin, CRP, Fe, TSAT): purely schematic — no published serial R-CHOP follow-up data available.

Active Ingredients — Application & Duration of Action

Hematological trend charts